Avtor/Urednik		Kandus, A; Bren, AF; Koselj, M; Kovač, D; Kveder, R
Naslov		Clinical evaluation of sandimmun neoral in kidney transplant patients
Tip		članek
Vir		Liječ Vjesn
Vol. in št.		Letnik 118, št. Suppl 2
Leto izdaje		1996
Obseg		str. 193-4
Jezik		eng
Abstrakt		The objective of our study was to evaluate efficacy, tolerability and safety of Sandimmun Neoral in kidney transplant patients (pts). Twenty-three stable pts, 9 females and 14 males, aged from 21 to 56 years, from 7 do 95 months after transplantation, were enroled in a 12-week period of this prospective study. Mean conversio ratio of dialy doses of Sandimmun/Sandimun Neoral was 1/1.03. Cyclosporine blood trough level was determined by fuorescence polarization immunossay using specific monoclonal antibody. At the beginning of the study mean daily dose of Sandimmun was 163 mg, and 155 mg of Sandimmun Neoral after 12 weeks. At the start, cyclosporine blood trough level (144+-38 ng/mL) was not significantly different from the level (133+-32 ng/mL) after 12 weeks. In 14 pts daily dose of Sandimmun Neoral was unchanged throughout the investigation. In this group, the mean coefficient of variation of cyclosporine blood trough level was 14% (range 8-14%). Kidney graft function was stable in all pts. The results suggest that Sandimmun Neoral is an effective immunosuppressive drug with low variability of blood trough level. No severe side effects were observed.
Deskriptorji		KIDNEY TRANSPLANTATION CYCLOSPORINE ADULT MIDDLE AGE